We performed an open right hemicolectomy and D2 dissection for a 70-year-old man diagnosed with cancer of the ascending colon. Postoperative chemotherapy was not initially planned for the patient; however, due to elevated tumor markers (CEA and CA19-9) and suspected recurrence, chemotherapy was initiated 6 months after surgery with sequential administration of TS-1 (alone), followed by TS-1 + irinotecan (IRIS), and then TS-1 + oxaliplatin (SOX). Based on CT and gastrointestinal endoscopic examinations, which revealed no signs of recurrence, and considering the patient’s preferences, follow-up care was initiated 2 years and 10 months after the surgery. Despite the absence of apparent recurrence, persistently elevated tumor marker levels were observed. The patient survived thereafter with no obvious signs of recurrence and 11 years after the surgery, he died due to pneumonia, suspected to be caused by aspiration. Tumor marker tests are valuable for estimating cancer progression before surgery, predicting recurrence, and assessing treatment effectiveness post-surgery. However, it is important to note that elevated levels of tumor markers can also be observed in patients with benign disorders. Diabetes mellitus may have played a role in the elevation of tumor markers in this particular case. In this report, we discuss this aspect briefly along with a review of the relevant literature.
View full abstract